Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

The partner of former Theranos founder and chief executive Elizabeth Holmes, Billy Evans, has reportedly raised millions of ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

BioMarin has been resetting its business with cuts in headcount and a narrowing of active programmes over the last year or so ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and ...